Histological features predictive of liver fibrosis in chronic hepatitis C infection

Journal of Clinical Pathology

Volumn 49, Issue 12, 1996, Pages 998-1004

  Paradis, V ^a,d   Mathurin, P ^b,d   Laurent, A ^d   Charlotte, F ^c   Vidaud, M ^d   Poynard, T ^b,d   Hoang, C ^c   Opolon, P ^b   Bedossa, P ^a,d  

^a BICÊTRE HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Service d'Anatomie Pathologique   (France)

^d CNRS   (France)

Author keywords

Chronic hepatitis C; In situ hybridisation; Liver fibrogenesis; TGF 1 mRNA

Indexed keywords

COLLAGEN TYPE 1; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030436442     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.12.998     Document Type: Article

References (30)

1. Soni P, Duseiko GM, Harrison TJ, Dhillon AP. Genetic diversity of hepatitis C virus: implications for pathogenesis, treatment, and prevention. Lancet 1995;345:562-6.
2. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-4.
3. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-19.
4. Liaw Y-F, Tai D-I, Chu C-M, Chen T-J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
5. Cooksley WGE, Bradbear RA, Robinson W, Harrison M, Halliday JW, Powell LW, et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986;6:345-8.
6. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992;15: 567-71.
7. Bach N, Thung SH, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992;15:572-7.
8. Lefkowitch JH, Schiff ER, Davis GL, Perrilo RP, Lindsay K, Bodenheimer HC, et al. Pathological diagnosis of chronic hepatitis C. A multicenter comparative study with chronic hepatitis B. Gastroenterology 1993;104:595-603.
9. Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: Collagens and glycoproteins. Semin Liver Dis 1990;10:1-10.
10. Gressner AM. Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur J Clin Chem Clin Biochem 1991;29:293-311.
11. Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1985;76:710-19.
12. Nakatsukasa H, Nagy P, Evarts RP, Hsia C, Marsden E, Thurgeirsson S. Cellular distribution of transforming growth factor-β1 and procollagen types I, III and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 1990;5:1833-43.
13. Biagini G. Liver fibrosis and extracellular matrix. J Hepatol 1989;8:115-24.
14. Zern MA, Czaja MJ, Weiner FR. The use of molecular hybridization techniques as tools to evaluate hepatic fibrogenesis. In: Rojkind M, ed. Connective tissue in health and disease. Boca Raton, FL: CRC Press, 1990:99-122.
15. Bachem M, Meyer D, Melchior R, Sell KM, Gressner AM. Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblast-like cells. A potential mechanism of self perpetuation in liver fibrogenesis. J Clin Invest 1992;89:19-27.
16. Sajus M, Olivi M, Vidaud D, Mathurin P, Opolon P, Poynard T, et al. Analysis of HCV genotypes by a fluorescent competitive oligonucleotide priming PCR (COP-PCR) [abstract]. Hepatology 1994;20:244a.
17. The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20:15-20.
18. Knodell KG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-5.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analyt Biochem 1987;162:156-9.
20. Foley KP, Leonard MW, Engel JD. Quantitation of RNA using the polymerase chain reaction. Trends Genet 1993;9: 380-5.
21. Bedossa P, Peltier E, Franco D, Poynard T, Lemaigre G. TGF 1 mRNA, protein and receptors in normal human liver, cirrhosis and hepatocellular carcinomas. Hepatology 1995;21:760-6.
22. Castilla A, Prieto J, Fausto N. Transforming growth factor-β1 and α in chronic liver disease. N Engl J Med 1991;324:933-6.
23. Annoni G, Weiner F, Zern MA. Increased transforming growth factor- 1 gene expression in human liver disease. J Hepatol 1992;14:259-64.
24. Nakatsukasa H, Evarts RP, Hsia C, Thorgeirsson SS. Transforming growth factor beta 1 and type I procollagen transcripts during regeneration and early fibrosis in rat liver. Lab Invest 1990;63:171-80.
25. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:9717-21.
26. Gilliland G, Perrin S, Blanchard K, Bunn HF. Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:2725-29.
27. Malizia G, Brunt EM, Peters MG, Rizzo A, Broekelmann TJ, McDonald JA. Growth factor and procollagen type I expression in human liver disease. Gastroenterology 1995; 108:145-56.
28. Milani S, Herbst H, Schuppan D, Surrenti C. Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol 1991;139:1221-29.
29. Roulot D, Durand H, Coste T, Rautureau J, Strosberg AD, Benarous R, et al. Quantitative analysis of transforming growth factor β1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease. Hepatology 1995;21:298-304.
30. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C, virus RNA levels and hepatitis C genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hapatology 1995;22:1050-7.